ENYO Pharma’s team is world class with a crucial mix of pharma senior leadership who proved their scientific excellence and financiers with deep understanding of pharma business.

Dr Jacky Vonderscher, PhD, co-founder and Chief Executive Officer

Jacky Vonderscher

  • Founder of Vonderscher&Co GmbH
  • Senior executive with a broad R&D experience in the pharmaceutical industry
  • Most recently Senior VP Head of Translation Research Sciences at Roche in USA and Switzerland (2010-2012)
  • Senior VP head of Molecular Medicine Labs at Roche (2008-2010)
  • Previously held other senior positions with Novartis in the USA and Switzerland (1979 to 2008)
  • Known for his leading role in the discovery and development of Sandimmum Neoral® in the 90s
  • Co-inventor on the first patents of Mycophenolic Acid Sodium salt (Myfortic® Product) and of Everolimus (Certican® and Afinitor® Products)
  • Board member of Inatherys, Step Pharma and ObsEva and SAB member of Inotrem SA
  • Board member of LyonBiopôle and IMI-JU (Innovative Medicines Initiative-Joint Undertaking)

Thomas Hess, CPA & MBA, Chief Financial Officer

Thomas Hess

  • Responsible for all financial and accounting activities
  • 35 years of experience in financial and executive management including: 10 years of publice accounting at KPMG and 13 years with emerging and growth-stage life science companies
  • Significant experience in public and private capital raising for healthcare companies
  • Currently serving as a Consulting CFO for Danforth Advisors LLC
  • Previously CFO of several healthcare companies including: Adolor (Nasdaq: ADLR), Yaupon Therapeutics and Genomind, Inc.
  • Education: University of Pittsburgh (MBA) and Pennsylvania State University (BS in Accounting)

Pete Leone, MBA, Head of Business Development & Licensing

Pete Leon

  • Responsible for Business development
  • More than 30 years of C-level experience at public and private biopharmaceutical companies, with over $6 billion in upfront payments and potential milestones from business development transactions that he led to closure
  • Various management roles at Arrowhead Pharmaceuticals (Nasdaq: ARWR), including business development, was CBO at Bicycle Therapeutics (Nasdaq: BCYC), and previously, a cofounder of three venture-backed companies, including Mersana Therapeutics (Nasdaq: MRSN)
  • Corporate and not-for-profit board member, including SeromYx Systems, Third Monday Foundation, and Nuestros Pequeños Hermanos – NPH USA Northeast region
  • Holds an A.B. in engineering science with pre-med studies from Dartmouth College and an MBA from the Stanford University Graduate School of Business

Dr Pietro Scalfaro, MD, MBA, SVP Head of Clinical Development Chief Medical Officer

Pietro Scalfaro

  • In charge of strategy and operational management of the clinical drug programs
  • Wide range experience in various roles in the healthcare sector, working notably in infectious diseases (HCV, via the development of Alisporivir), septicaemia, oncology, Alzheimer’s disease and cardio-respiratory diseases
  • Set up a Personalised Medicine Business Unit at Debiopharm Group and involved during start-up of eHealth and diagnostic companies (Biocartis, Sophia Genetics, Agendia, Immunexpress, Pryv, Orphanalytics)
  • Practicing physician, with degrees from the University of Lausanne and the Swiss Medical Association in Paediatrics, Intensive Care and MBA

Dr Raphaël Darteil, PhD, SVP Head of non-clinical Development & Profiling

Raphaël Darteil

  • Responsible for non-clinical development and in vitro / in vivo compound profiling
  • More than 20 years of experience in R&D project and portfolio management in the Pharma and Biotech industries
  • Scientific expertise in metabolic diseases (including NAFLD/NASH) and in the Nuclear Receptor field
  • COO and Member of the board at Genfit
  • Various positions in the department of Gene Therapy of Aventis both in France and in the US
  • Co-inventor of the patent protecting the use of Elafibranor (Phase III) for the treatment of NASH patients
  • He owns a PhD in Molecular and Cellular Biology from the University Claude Bernard Lyon I

Keltoum Medji, MBA, VP Finance and Strategic Development

Keltoum Medji

  • Responsible for all finance activities including fundraising, investors relations, strategic partnerships
  • More than 20 years’ experience in Orthopedic business supporting growth by an increased collaboration with supply chain & commercial organizations
  • Strong experience in change management through diverse organizational changes as M&A, restructuring, reorganizations
  • Graduated with a Master’s degree in Economics & Business Management and an MBA from EM Lyon Business School

Hélène Grimm, VP Legal Affairs & Board Secretary

Hélène Grimm

  • Responsible for legal affairs and Secretary of the Board of Directors
  • 18 years’ experience as in-house legal counsel and legal manager in international organizations including pharma players (Bayer, Mylan)
  • Core competencies in contracts, corporate / governance, compliance, intellectual property and insurances
  • Graduated with a Master degree in private law as well as with an MBA in management & business law